A Phase 1b, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Clinical Activity of CND261 in Patients With Seropositive Rheumatoid Arthritis
Latest Information Update: 11 Aug 2025
At a glance
- Drugs CND 261 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Candid Therapeutics
Most Recent Events
- 15 Jul 2025 New trial record